CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,230,845
- in 7 filings, $1.6M under 10b5-1 plans
Net −$2,230,845. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 37 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-10-01 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +521 | $2.48 | $1K | 521 |
| 2024-10-01 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −521 | $27.54 | $14K | 0 |
| 2024-10-01 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −521 | 192,358 | ||
| 2024-10-01 | Heyman Richard A. Director | Sale 10b5-1 | −518 | $27.54 | $14K | 128,585 |
| 2024-09-30 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +2,000 | $2.48 | $5K | 2,000 |
| 2024-09-30 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −2,000 | $25.33 | $51K | 0 |
| 2024-09-30 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −2,000 | 192,879 | ||
| 2024-09-27 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +4,250 | $2.48 | $11K | 4,250 |
| 2024-09-27 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −4,250 | $24.27 | $103K | 0 |
| 2024-09-27 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −4,250 | 194,879 | ||
| 2024-09-16 | Heyman Richard A. Director | Sale 10b5-1 | −1,270 | $22.41 | $28K | 129,103 |
| 2024-08-29 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −11,950 | $22.48 | $269K | 1,077,986 |
| 2024-08-29 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −50 | $23.08 | $1K | 1,077,936 |
| 2024-08-27 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +4,250 | $2.48 | $11K | 4,250 |
| 2024-08-27 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −4,250 | $22.54 | $96K | 0 |
| 2024-08-27 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −4,250 | 199,129 | ||
| 2024-08-26 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −12,000 | $22.89 | $275K | 1,049,255 |
| 2024-08-15 | Heyman Richard A. Director | Sale 10b5-1 | −650 | $22.82 | $15K | 130,993 |
| 2024-08-15 | Heyman Richard A. Director | Sale 10b5-1 | −620 | $23.70 | $15K | 130,373 |
| 2024-07-31 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −3,099 | $27.56 | $85K | 1,089,936 |
Page 17 of 37 · 724 trades